Technology in Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231204198. doi: 10.1177/15330338231204198.ABSTRACTAdoptive cell immunotherapy (ACT) is an innovative promising treatment for tumors. ACT is characterized by the infusion of active anti-tumor immune cells (specific and non-specific) into patients to kill tumor cells either directly or indirectly by stimulating the body's immune system. The patient's (autologous) or a donor's (allogeneic) immune cells are used to improve immune function. Chimeric antigen receptor (CAR) T cells (CAR-T) is a type of ACT that has gained attention. T cells from the peripheral blood are geneticall...
Source: Technology in Cancer Research and Treatment - December 1, 2023 Category: Cancer & Oncology Authors: Dong Zhao Dantong Zhu Fei Cai Mingzhe Jiang Xuefei Liu Tingting Li Zhendong Zheng Source Type: research

Accuracy and Feasibility of Synthetic CT for Lung Adaptive Radiotherapy: A Phantom Study
CONCLUSION: The synthetic computed tomography images generated from Velocity were close to the real images in anatomy and dosimetry, which can make clinical lung adaptive radiotherapy possible based on the actual patient anatomy during treatment.PMID:38037343 | DOI:10.1177/15330338231218161 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 1, 2023 Category: Cancer & Oncology Authors: Ruifeng Zhao Xingliu Wang Huanhai Wei Source Type: research

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies.PMID:38031361 | PMC:PMC10687954 | DOI:10.1177/15330338231218152 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 30, 2023 Category: Cancer & Oncology Authors: Binwei Lin Jinjia Fan Fang Liu Yixue Wen Jie Li Feng Gao Yu Zhang Gang Feng Xiaobo Du Wenzhi Chen Source Type: research

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies.PMID:38031361 | DOI:10.1177/15330338231218152 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 30, 2023 Category: Cancer & Oncology Authors: Binwei Lin Jinjia Fan Fang Liu Yixue Wen Jie Li Feng Gao Yu Zhang Gang Feng Xiaobo Du Wenzhi Chen Source Type: research

Development and Validation of a Prediction Model for Venous Thrombus Embolism (VTE) in Patients With Colorectal Cancer
This study retrospectively examined 528 newly diagnosed colorectal cancer patients from January 2019 to January 2021. Specified logistic regression models were employed to screen the factors and establish prediction tools based on nomograms according to the final included variables. Discrimination, calibration, and clinical applicability were used to assess the performance of screening tools. In addition, internal verifications were conducted through 10-fold cross-verification, leave-one-out cross-validation, and Bootstrap verification. Four risk factors, closely related to the occurrence of VTE in colorectal cancer patien...
Source: Technology in Cancer Research and Treatment - November 29, 2023 Category: Cancer & Oncology Authors: Wei-Juan Tan Lu Chen Sheng-Jie Yang Bao-Ying Zhang Ming-Li Sun Yu-Bin Lin Xing-He Wang Source Type: research

Prognostic Significance of Advanced Age in Patients with T1a Renal Cell Carcinoma Treated by Microwave Ablation: A 16-Year Experience
CONCLUSIONS: Advanced age exerts adverse effects and significantly protective effects on OS and PFS, respectively, in T1a RCC patients with a CCI ≥ 3. According to our study, elderly patients with T1a RCC underwent radical MWA may yield a better medium-term OS relative to AS.PMID:38018134 | PMC:PMC10686028 | DOI:10.1177/15330338231183585 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 29, 2023 Category: Cancer & Oncology Authors: Qidi Hou Yaxi Wang Dongyun Zhang Yanchun Luo Linan Dong Mengjuan Mu Jie Yu Ping Liang Source Type: research

Using Bland-Altman Analysis to Identify Appropriate Clonogenic Assay Colony Counting Techniques
CONCLUSION: Counting with a manual pen demonstrated significant bias when compared to microscopic and semiautomated colony counts; 2 methods were deemed to be interchangeable. Thus, training algorithms based on manual counts may introduce this bias as well. Algorithms trained to select colonies based on size (pixels2) and shape (circularity) should be prioritized. Solely relying on Bland-Altman or correlational analyses when determining method interchangeability should be avoided; they rather should be used in conjunction.PMID:37997353 | PMC:PMC10668582 | DOI:10.1177/15330338231214250 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 24, 2023 Category: Cancer & Oncology Authors: Seth Buryska Sanjana Arji Beverly Wuertz Frank Ondrey Source Type: research

Using Bland-Altman Analysis to Identify Appropriate Clonogenic Assay Colony Counting Techniques
CONCLUSION: Counting with a manual pen demonstrated significant bias when compared to microscopic and semiautomated colony counts; 2 methods were deemed to be interchangeable. Thus, training algorithms based on manual counts may introduce this bias as well. Algorithms trained to select colonies based on size (pixels2) and shape (circularity) should be prioritized. Solely relying on Bland-Altman or correlational analyses when determining method interchangeability should be avoided; they rather should be used in conjunction.PMID:37997353 | DOI:10.1177/15330338231214250 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 24, 2023 Category: Cancer & Oncology Authors: Seth Buryska Sanjana Arji Beverly Wuertz Frank Ondrey Source Type: research

3D-US and CBCT Dual-guided Radiotherapy for Postoperative Uterine Malignancy: A Primary Workflow Set-up
Conclusion: A primary workflow of 3D-US and CBCT dual-guided radiotherapy has been established, which showed great therapeutic potential with mild to moderate urinary and rectal toxicity for postoperative uterine malignancy patients. But the clinical outcomes of this non-invasive technique need to be investigated further.PMID:37993995 | PMC:PMC10666818 | DOI:10.1177/15330338231212082 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 23, 2023 Category: Cancer & Oncology Authors: Yang Li Zhen Gong Mengyu Liu Huixin Li Han Gao Chang Guo Le Yu Chenjing Zhu Zhihua Sun Li Sun Hanzi Xu Xia He Source Type: research

3D-US and CBCT Dual-guided Radiotherapy for Postoperative Uterine Malignancy: A Primary Workflow Set-up
Conclusion: A primary workflow of 3D-US and CBCT dual-guided radiotherapy has been established, which showed great therapeutic potential with mild to moderate urinary and rectal toxicity for postoperative uterine malignancy patients. But the clinical outcomes of this non-invasive technique need to be investigated further.PMID:37993995 | DOI:10.1177/15330338231212082 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - November 23, 2023 Category: Cancer & Oncology Authors: Yang Li Zhen Gong Mengyu Liu Huixin Li Han Gao Chang Guo Le Yu Chenjing Zhu Zhihua Sun Li Sun Hanzi Xu Xia He Source Type: research

Global Trends and Prospects Regarding Exosomes in Cancer Immunology Research Over the Past 10 Years
Conclusion: The publication trend shows that cooperation between different countries and institutions contributes to the development of this field. Researchers should continue to extend collaborations for further advances. The rising relative research interest indicated that this is a hot topic with great research potential. Macrophages polarization and PD-L1 application in tumor immunotherapy are worthy of further research. Hotspots will likely transfer from mechanistic research to clinical research, particularly for methods to increase the survival rate and improve the prognosis of cancer patients.PMID:37990510 | DOI:10....
Source: Technology in Cancer Research and Treatment - November 22, 2023 Category: Cancer & Oncology Authors: Demeng Xia Rui Wu Sheng Wang Gaoqi Chen Ye Lu Liang Zhao Source Type: research

Role of Exosomal Non-Coding RNA in the Tumour Microenvironment of Genitourinary System Tumours
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231198348. doi: 10.1177/15330338231198348.ABSTRACTIn recent years, genitourinary system tumors are common in people of all ages, seriously affecting the quality of life of patients, the pathogenesis and treatment of these diseases are constantly being updated and improved. Exosomes, with a lipid bilayer that enable delivery of their contents into body fluids or other cells. Exosomes can regulate the tumor microenvironment, and play an important role in tumor development. In turn, cellular and non-cellular components of tumor microenvironment also affect the occurrence, prog...
Source: Technology in Cancer Research and Treatment - November 20, 2023 Category: Cancer & Oncology Authors: Shuang Wu Chao Mu Jia-Jia Sun Xin-Rong Hu Yun-Hong Yao Source Type: research